BICYCLE
LIVE

Serial Number

79406165

Owner

Bicycletx Limited

Attorney

CHRISTINA M. LICURSI

Filing Date

May 21, 2024

Add to watchlist:

No watchlists yet
View on USPTO

BICYCLE Trademark

Serial Number: 79406165 • Registration: 8112696

BICYCLE is a trademark filed by Bicycletx Limited on May 21, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Bicycletx Limited (33 trademarks)

Blocks A & B Portway Building,

Entity Type: 99

Trademark Details

Filing Date

May 21, 2024

Registration Date

January 27, 2026

Published for Opposition

March 18, 2025

Goods & Services

Scientific research; scientific study and research in the field of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; laboratory research services in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; providing information, consultancy and advisory services relating to the design, planning and implementation of scientific and clinical research for others

Medical services; medical testing for diagnostic or treatment purposes; healthcare services; pharmaceutical services, namely, pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in connection with respiratory disease; medical services in connection with cardiovascular disease; medical services in connection with metabolic disease; medical services in connection with the treatment and/or prevention of viral infections; medical services in connection with diagnostics and imaging; medical services in connection with renal disease; medical services in connection with gastrointestinal disease; medical services in connection with muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in connection with respiratory disease; pharmaceutical compounding services in connection with cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid

Pharmaceutical products, namely, pharmaceutical preparations for use in oncology for both solid and liquid tumours, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical preparations for use as diagnostics, namely, diagnostic preparations for medical use; pharmaceutical preparations for use as clinical imaging agents for positron emission tomography use

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Apr 27, 2026 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Mar 26, 2026 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Mar 9, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Mar 9, 2026 OPNR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jan 27, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jan 27, 2026 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Jan 2, 2026 TMBN
OPPOSITION TERMINATED NO. 999999
Jan 2, 2026 OP.T
OPPOSITION DISMISSED NO. 999999
Jan 2, 2026 OP.D
REFUSAL PROCESSED BY IB
Aug 8, 2025 RFNT
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
Jul 21, 2025 ETOP
OPPOSITION INSTITUTED NO. 999999
Jul 21, 2025 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Jul 17, 2025 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Jul 17, 2025 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Apr 14, 2025 ETOF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 26, 2025 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Mar 26, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 26, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 26, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 26, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 26, 2025 COAR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 18, 2025 NPUB
PUBLISHED FOR OPPOSITION
Mar 18, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 12, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 25, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 21, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Feb 21, 2025 TROA
REFUSAL PROCESSED BY IB
Dec 29, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 10, 2024 RFCS
REFUSAL PROCESSED BY MPU
Dec 10, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Nov 26, 2024 RFCR
NON-FINAL ACTION WRITTEN
Nov 25, 2024 CNRT
ASSIGNED TO EXAMINER
Nov 16, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Oct 15, 2024 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 15, 2024 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Oct 15, 2024 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Oct 10, 2024 REPR